Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Since there is no cure, disease surveillance and treatment have to be continued long term. Polycythemia vera is a medical ...

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...

Hence, just like low haemoglobin levels (less than 13.2 g/dL for men and 11.6 g/dL for women) necessitate medical ...

Hi. I'm Ron. I'm a polycythemia patient, and I've had the disease for over 25 years. I was originally diagnosed at the age of 38. And I'm here to talk to you about symptom management and talking ...

The prevalence JAK2 V617F proteins in the general population is about 0.2%. In people with polycythemia vera (PV), JAK2 V617F mutations are present in 96% of cases. JAK2 mutations lead to health ...

An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of ...

In this randomized controlled trial, among patients with severe hypoxemia, long-term oxygen therapy used for 24 hours per day ...

Czech National Bank trimmed its position in Incyte Co. (NASDAQ:INCY – Free Report) by 8.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The ...